Adam Laponis, Chief Financial Officer of Twist Bioscience Corp (NASDAQ:TWST), sold 2597 shares of common stock on April 9, 2026, at a price of $49.889, for a total transaction value of $129561. The sale came as shares trade at $50.38, near their 52-week high of $57.88, following a strong 59% surge over the past six months.
Following the transaction, Laponis directly owns 125694 shares of Twist Bioscience Corp. According to InvestingPro analysis, the stock appears overvalued relative to its Fair Value estimate, placing it among companies on the most overvalued list. Investors should note that InvestingPro offers 9 additional exclusive tips for TWST, including insights on the company’s profitability outlook and financial health.
The sale was executed to cover tax withholding obligations related to the vesting of restricted stock units, as mandated by Twist Bioscience’s equity incentive plans.
In other recent news, Twist Bioscience Corporation reported its first-quarter earnings for fiscal year 2026, showing a revenue of $103.7 million, which exceeded analysts’ forecasts by 2.96%. However, the company’s earnings per share (EPS) were below expectations, coming in at -$0.50 compared to the projected -$0.43. Additionally, Twist Bioscience announced a licensing agreement with Invenra Inc. for the B-Body bispecific antibody platform, allowing Twist to become a co-exclusive provider of this technology. This move aims to enhance Twist’s antibody discovery services.
Shareholders of Twist Bioscience also participated in the 2026 Annual Meeting, where they approved director elections and executive compensation. The meeting saw representation of approximately 91.81% of the company’s outstanding shares eligible to vote. These developments highlight the company’s strategic initiatives and shareholder engagement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Most traders know the market. The hard part is the moment — which stock, right now, at what price. Chart analysis handles that. Our Vision AI scans your charts, spots the pattern before it plays out, and hands you the complete setup: entry, exit, done in under 60 seconds. Investors are already reporting a high accuracy rate, even on penny stocks.